Relation of functional improvement in congestive heart failure after quinapril therapy to peripheral limitation

• Published in: The American journal of cardiology 1997-03, Vol.79 (5), p.635-638
• Main Authors: Jondeau, Guillaume, Dib, Jean-Claude, Dubourg, Olivier, Bourdarias, Jean-Pierre
• Format: Article
• Language: English
• Subjects: Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Arm - physiology; Biological and medical sciences; Cardiovascular system; Coronary Circulation - drug effects; Drug therapy; Exercise Test; Female; Follow-Up Studies; Heart failure; Heart Failure - drug therapy; Heart Failure - etiology; Heart Failure - physiopathology; Humans; Hyperemia - physiopathology; Isoquinolines - therapeutic use; Leg - blood supply; Leg - physiology; Male; Medical sciences; Middle Aged; Muscle, Skeletal - blood supply; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Oxygen; Oxygen Consumption - drug effects; Pharmacology. Drug treatments; Physical Exertion - physiology; Quinapril; Regional Blood Flow - drug effects; Respiration - drug effects; Stroke Volume; Tetrahydroisoquinolines; Vasodilation; Vasodilator agents. Cerebral vasodilators; Ventricular Dysfunction, Left - complications
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(96)00830-2

Angiotensin-converting enzyme inhibitors have been shown to increase maximal muscle blood flow in parallel to peakV̇O2 in patients with congestive heart failure (CHF). Whether this increase shifts factors limiting peak aerobic capacity from periphery (skeletal muscle or vessels) to central factors (cardiac or respiratory) is unknown. Comparison of peak oxygen consumption (V̇O2) obtained during leg cycling (V̇O2 leg) with peakV̇O2 obtained during combined leg cycling and arm cranking (V̇O2 arm + leg) allows determination of the relative role of central or peripheral factors. We comparedV̇O2 leg withV̇O2 arm + leg before and after 3 months of therapy with quinapril 40 mg in 16 patients with CHF (age 53 ± 13 years) due to left ventricular systolic dysfunction (ejection fraction 0.25 ± 0.07). Before quinapril,V̇O2 arm + leg was significantly higher thanV̇O2 leg (19.0 ± 3.3 vs 16.9 ± 3.8 ml/kg/min, p < 0.001), whereas after therapy these 2 values were similar (20.3 ± 4.3 vs 21.0 ± 4.3 ml/kg/min; p = NS), indicating that patients were no longer limited by peripheral factors. Besides,V̇O2 leg increase after therapy was higher in patients in whom difference betweenV̇O2arm + leg andV̇O2 leg was the greatest (i.e., in patients who were initially more limited by peripheral factors). Simultaneously, calf peak reactive hyperemia and circumference significantly increased, indicating an improvement in vascular dilating capacity and an increase in skeletal muscle mass. No significant modification occurred in the forearm. Thus, patients who improved the most after 3 months of quinapril therapy were those who were initially limited by peripheral factors. The restricting role of these factors was reduced after quinapril therapy.